Clinical Cancer Research
Clinical Cancer Research
4 years ago

Phase 1b/2 Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors.

Dirk J Reitsma, Kazuhiro Takahashi, Richard H Tran, Austin Combest, Juneko E Grilley-Olson, Atsuhiro Masada, Jaikrishna Balkissoon, Vivek Subbiah, Lyudmila Bazhenova, Iulian Bobe, Aaron Camp, Atsushi Osada, Neelesh Sharma
Purpose NC-6004, a novel cisplatin nanoparticle developed using micellar technology exhibits sustained release of cisplatin and selective distribution to tumors. Preclinical data demonstrated a favorable tolerability profile and preserved or improved anti-tumor activity compared to cisplatin across animal models. We evaluated the safety and tolerability of NC-6004 and gemcitabine using a Bayesian continual reassessment model (N-CRM) to determine the optimal dose. Experimental Design Patients with advanced solid tumors received NC-6004 at 60-180mg/m2 on Day 1 and gemcitabine at 1250 mg/m2 on Days 1 and 8 every three weeks. Dose escalation of NC-6004 began with a single patient run-in until a dose limiting toxicity occurred at 180mg/m2. Cohorts of four patients were enrolled at doses predicted by the N-CRM. The maximum tolerated dose (MTD) was defined as having the greatest probability of target toxicity < 25%. Quality of life was assessed using EORTC-QLQ-C30. Results Among 22 patients, the most common Grade 3/4 hematologic adverse events were leukopenia (68%) and thrombocytopenia (59%). Of 20 pretreated patients evaluable for response, half were previously exposed to a platinum agent. The MTD was 135 mg/m2. Nine patients were treated at the MTD with median treatment duration of 15 weeks (range, 3-50). Tumor shrinkage occurred in 11 (55%), partial responses in 3 (15%) and stable disease in 14 (70%). Most patients reported stable or improved EORTC QLQ-C30 scores. Conclusions Greater cisplatin equivalent doses were achieved with no clinically significant neuro-, oto- or nephrotoxicity. These data demonstrate tolerability and promising activity of NC-6004 in combination with gemcitabine.

Publisher URL: http://doi.org/10.1158/1078-0432.CCR-17-1114

DOI: 10.1158/1078-0432.CCR-17-1114

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.